Abstracts Archive - Page 151 of 2607 - ACR Meeting Abstracts

Abstract Number: 0435 • ACR Convergence 2025
Comparative Outcomes in Seropositive and Seronegative Rheumatoid Arthritis: A Retrospective Cohort Study
Ahmad Alomari¹, Reem Elmusa², Nikita Shah³, Miguel Rodriguez⁴ and Diala Alawneh⁵, ¹UCF- North Florida hospital, Gainesville, FL, ²UCF/ HCA - North florida hospital, Gainesville, FL, ³UCF/HCA Florida North Florida Hospital, Gainesville, FL, ⁴SIMED Rheumatology, Gainesville, FL, ⁵University of Florida, Gainesville, FL
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that manifests as either seropositive or seronegative subtypes. Seropositive RA, characterized by the presence of autoantibodies…
Abstract Number: 0448 • ACR Convergence 2025
Implementing Artificial Intelligence to Identify Rheumatoid Arthritis Flares Using Electronic Medical Records Processed with Privacy-Preserving Large Language Models: A Pilot Study
Ioannis Koulas¹, Nikolaos Tsaftaridis², Marios Gkionis³, Giancarlo Paternoster⁴, Sunit Jariwala⁵ and Konstantinos Loupasakis⁶, ¹Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²The Feinstein Institutes for Medical Research, Manhasset, ³NTNU, Department of Engineering Cybernetics, Trondheim, Norway, ⁴Albert Einstein College of Medicine, Bronx, NY, ⁵Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁶Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Although Large Language Models (LLMs) have been successfully used in the analysis of data from Electronic Health Records (EHRs), their implementation in the field…
Abstract Number: 0394 • ACR Convergence 2025
Predictors of quality of Life in a longitudinal cohort of patients with Uveitis, Juvenile Idiopathic Arthritis, and JIA-associated uveitis
andressa Guariento Ferreira Alves¹, Amy Cassedy², Virginia Miraldi Utz³, Alexandra Duell³, Megan Quinlan-Waters⁴, Nicole Reitz⁵, Sheila Angeles-Han⁶ and Melissa Lerman⁷, ¹The Children's Hospital of Philadelphia, Philadelphia, PA, ²Cincinnati Children's hospital medical center, cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, CCHMC, ⁵Department of Mental Health, St. Louis, MO, ⁶Cincinnati Children's Hospital, Cincinnati, OH, ⁷Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Uveitis, juvenile idiopathic arthritis (JIA), and JIA-associated uveitis (JIA-U) greatly influence children's quality of life (QOL). Our aim is to identify demographic, disease, and…
Abstract Number: 0050 • ACR Convergence 2025
TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis
Preeyam Patel¹, Matthew Siegel², Emily Lewis³, David Giles³, Justin LaFountaine³, Joshua Friedman³ and Andy Spencer³, ¹Spyre Therapeutics, Waltham, ²Spyre Therapeutics, Menlo Park, CA, ³Spyre Therapeutics, Waltham, MA
Background/Purpose: The development of disease-modifying anti-rheumatic drugs (DMARDs) has reduced disease activity in patients living with rheumatic diseases. Despite this, there is continued unmet need…
Abstract Number: 0503 • ACR Convergence 2025
Impact of Olokizumab on Pain in Rheumatoid Arthritis: a Meta-analysis
Andrey E. Karateev¹, Sofia Kuzkina², Alina Egorova³ and Elena Y. Polishchuk¹, ¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ²R-Pharm, Moscow, Russia, ³R-Pharm JSC, Moscow, Russia
Background/Purpose: Pain is one of the most debilitating symptoms of rheumatoid arthritis (RA) and a major contributor to reduced quality of life. Persistent joint pain…
Abstract Number: 0475 • ACR Convergence 2025
Drug Discontinuation in Inflammatory Arthritis Following Mandatory Non-Medical Switching from Originator to Biosimilar in Quebec, Canada
Cristiano Moura¹, Luck Lukusa², Denis Choquette³, Gilles Boire⁴, Nathalie Carrier⁵, Autumn Neville² and Sasha Bernatsky⁶, ¹Research Institute of the McGill University Health Center, Montréal, Canada, ²Research Institute of the McGill University Health Centre, Montreal, Canada, ³Institut de Rhumatologie de Montréal, Saint-Donat-de-Montcalm, Canada, ⁴Retired, Sherbrooke, QC, Canada, ⁵Centre integré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie-CHUS), Sherbrooke, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: In April 2022, the Canadian province of Quebec introduced a mandatory non-medical switch to biosimilars for persons on bio-originators to manage healthcare costs. Our…
Abstract Number: 0280 • ACR Convergence 2025
Sera from dermatomyositis patients induce muscle weakness via activation of type I interferon (IFN) receptors.
Suchada Kaewin¹, Cecilia Leijding², Kristofer Andreasson², Helene Alexanderson³, Stefano Gastaldello¹, Ingrid Lundberg² and Daniel C. Andersson², ¹Karolinska Institutet, inst fysiologi och farmakologi, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Dermatomyositis (DM) is a major subtype of idiopathic inflammatory myopathies (IIMs) and characterized by muscle weakness, systemic inflammation and cutaneous lesions. Expression of type…
Abstract Number: 0492 • ACR Convergence 2025
Outcomes of Total Knee Replacement in Patients with Rheumatoid Arthritis: A National Inpatient Sample Database Analysis
karun Shrestha¹, Pravakar Parajuli², Anil Regmi³, Prakriti Subedi⁴, Manoj Ghimire⁵, Sajana Poudel⁶, Mohammed Hasan⁷, Mahmoud Hashim⁸, Veera Durga Vaishnavi Kurra⁹ and ClementT Taoge¹⁰, ¹Department of Internal Medicine, St. Barnabas Hospital, SBH Health System, Bronx, NY ¹⁰⁴⁵⁷, USA, BRONX, NY, ²Patan Academy of Health Sciences-School of Medicine (PAHS-SOM), Lalitpur, Bagmati, Nepal, ³Parkview Health, Fort Wayne, IN, ⁴St. Barnabas Hospital, Bronx, NY, ⁵St Barnabas Hospital, BRONX, NY, ⁶Cook County Health, CHICAGO, NY, ⁷Parkview Medical Center, Pueblo, CO, ⁸SBH Health System, New Rochelle, NY, ⁹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Albert Einstein College of Medicine - Montefiore Medical Center, Bronx
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease of the joints with an estimated prevalence of 0.5% of people. Nearly 25% of RA patients…
Abstract Number: 0452 • ACR Convergence 2025
Ten-Year Real-World Longitudinal Analysis of Bone Mineral Density in Rheumatoid Arthritis: Impact of RA and Osteoporosis Treatments
Keigo Hayashi¹, Kei Hirose², Natsuki Kubota¹, Yuya Terajima¹, Kazuya Matsumoto¹, Takato Nakadoi¹, Shoichi Nawachi¹, Yoshia Miyawaki³, Eri Katsuyama⁴, Takayuki Katsuyama¹, Haruki Watanabe¹, Mariko Narazaki¹, Yoshinori Matsumoto¹ and Jun Wada¹, ¹Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama city, Japan, ³Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ⁴Faculty of Health Science, Okayama University Medical School, Graduate School of Health Sciences, Boston, MA
Background/Purpose: Despite advancements in rheumatoid arthritis (RA) and osteoporosis management that have improved patient outcomes, osteoporosis continues to be a significant clinical concern in RA.…
Abstract Number: 0519 • ACR Convergence 2025
A Multi-criterion Feature Integration Framework for Accurate Diagnosis of Primary Sjögren’s Syndrome Using Routine Laboratory Tests: A Multicentre, Retrospective Cohort study
Shu Liu¹, Guanhao Wu¹, Mengge Pan¹, Qi Sun², Jingchen Gao¹, Xianming Long³, Chaogui Tang⁴, Xinran Yuan¹ and Lingyun Sun¹, ¹Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China (People's Republic), ²Department of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong, China, Nantong, China (People's Republic), ³The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China (People's Republic), ⁴The Affiliated Huaian First People’s Hospital of Nanjing Medical University, Huai’an First People’s Hospital, Nanjing Medical University, Huaian, China (People's Republic)
Background/Purpose: Primary Sjögren's syndrome (pSS) is a prevalent systemic autoimmune disorder. However, the early and accurate diagnosis of pSS remains challenging due to its non-specific…
Abstract Number: 0035 • ACR Convergence 2025
Clinical and Transcriptomic Heterogeneity in Patients With RA: A Multi-Centric International Study of Anti-TNF Response
Maryna Borshchivska¹, Thibault Helleputte¹, Laurent Meric de Bellefon², Silvana di Romana³, Elsa Vieira-Sousa⁴, Vasco Romão⁴, João Eurico Fonseca⁵, Alla Ishchenko⁶, Patrick Verschueren⁶, Ruth Wittoek⁷, Peggy jacques⁷, Dirk Elewaut⁸, Bernard Lauwerys⁹ and Patrick Durez¹⁰, ¹DNAlytics, Louvain-la-Neuve, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Belgium, ³Department of Rheumatology, Saint Pierre University Hospital, Brussels, Belgium, ⁴Faculdade Medicina, Universidade de Lisboa, ULS Santa Maria, Centro Académico Medicina de Lisboa, Lisboa, Portugal, ⁵Faculdade Medicina, Universidade de Lisboa, ULS Santa Maria, Centro Académico Medicina de Lisboa, Lisboa, Lisboa, Portugal, ⁶Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium, ⁷VIB Center for Inflammation Research, Ghent University and Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁸VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ⁹Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, ¹⁰Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Brussels Hoofdstedelijk Gewest, Belgium

Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that can lead to joint damage and disability. Although methotrexate is the standard first-line treatment, about…
Abstract Number: 0413 • ACR Convergence 2025
Improving Access to Timely Joint Injections for Pediatric Rheumatology Patients – A Quality Improvement Initiative
Kendra Lauer¹, Vidya Sivaraman², Melissa Argraves³, Ysabella Esteban⁴, Laura Pratt⁵, Alysha Taxter⁶, Shoghik Akoghlanian³, Kelly Wise⁷, Kathryn Anliker³, Jonnie Hughes³, James Booker³, Ashlee Leone³ and Edward Oberle³, ¹Nationwide Children's Hospital, Dublin, OH, ²Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ³Nationwide Children's Hospital, Columbus, OH, ⁴Nationwide Children's Hospital, Plain City, OH, ⁵Nationwide Children's Hospital/The Ohio State University College of Medicine, Columbus, OH, ⁶Nationwide Children's, Columbus, OH, ⁷Nationwide Children's Hospital, Hilliard, OH
Background/Purpose: Timely treatment for juvenile idiopathic arthritis (JIA) is essential for disease remission and decreasing risk of long-term morbidity. Intra-articular corticosteroid joint injections can treat…
Abstract Number: 0288 • ACR Convergence 2025
Predictors and Characteristics of Objective Flares in Adult Dermatomyositis
Didem Saygin¹, York Wang², Kathryn C. Fitzgerald³, Jemima Albayda⁴, Julie Paik⁵, Eleni Tiniakou⁶, Brittany L Adler², Andrew Mammen⁷, Lisa Christopher-Stine⁴ and Chris Mecoli², ¹Rush University Medical Center, Chicago, IL, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Johns Hopkins Rheumatology, Baltimore, MD, ⁶UT Health Science Houston, Houston, TX, ⁷NIH, Bethesda, MD
Background/Purpose: Dermatomyositis (DM) is a chronic systemic autoimmune disease with a heterogenous clinical course. Flares often lead to increased morbidity, health care utilization, and reduced…
Abstract Number: 0459 • ACR Convergence 2025
Risk Factors for Acute Exacerbation in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease
Rinko Katsuda¹, Akiko Kitagawa¹, Masayuki Azukizawa², Musuzu Fujimori¹ and Tetsuji Kawamura³, ¹Department of Rheumatology, NHO Himeji Medical Center, Japan, Himeji, Japan, ²Department of Orthopaedic Surgery, NHO Himeji Medical Center, Japan, Himeji, Japan, ³Department of Respiratory Medicine, NHO Himeji Medical Center, Japan, Himeji, Japan
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a common and serious extra-articular manifestation of RA, contributing to ~10% of RA-related mortality. Acute exacerbation (AE)…
Abstract Number: 0525 • ACR Convergence 2025
Cost-of-Illness Among Newly Diagnosed Patients with Psoriatic Arthritis in Sweden
Sofia Wittgren¹, Sofia Exarchou², Daniela Di Giuseppe³, Ulf Lindström⁴, Tor Olofsson¹, Lennart T. H. Jacobsson⁴, Johan Askling³ and Johan Karlsson Wallman¹, ¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Skane Lan, Sweden, ²Lund University, Åkarp, Skane Lan, Sweden, ³Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Division, Stockholm, Stockholms Lan, Sweden, ⁴Gothenburg University, Sahlgrenska Academy, Department of Rheumatology and Inflammation Research, Gothenburg, Vastra Gotaland, Sweden
Background/Purpose: Up-to-date information on the cost-of-illness of psoriatic arthritis (PsA) is important for healthcare/social insurance system budgeting and to highlight unmet needs in PsA care.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].